Activation of human leukocytes by lipid A from E. coli strains adapted to quaternary ammonium salt and amine oxide
Language English Country United States Media print
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
14533488
DOI
10.1007/bf02931338
Knihovny.cz E-resources
- MeSH
- Drug Resistance, Bacterial MeSH
- Dimethylamines pharmacology MeSH
- Escherichia coli drug effects immunology physiology MeSH
- Phagocytosis MeSH
- Quaternary Ammonium Compounds pharmacology MeSH
- Leukocytes enzymology immunology metabolism MeSH
- Humans MeSH
- Lipid A analogs & derivatives immunology MeSH
- Muramidase metabolism MeSH
- Peroxidase metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Dimethylamines MeSH
- diphosphoryl lipid A MeSH Browser
- Quaternary Ammonium Compounds MeSH
- Lipid A MeSH
- monophosphoryl lipid A MeSH Browser
- Muramidase MeSH
- N-(1-methyldodecyl)-N,N,N-trimethylammonium MeSH Browser
- N,N-dimethyl-1-methyldodecylamine oxide MeSH Browser
- Peroxidase MeSH
The immunomodulatory activities of monophosphoryl lipid A (MLA) and diphosphoryl lipid A analogues obtained from the sensitive strain of E. coli and from the resistant strains adapted to a quaternary ammonium salt and an amine oxide were compared. All analogues considerably stimulated the activity of human leukocytes although the analogue from the sensitive strain at a higher concentration significantly suppressed phagocytosis. The MLA analogue exhibited a suppressive effect on the microbicidal activity of human leukocytes against E. coli and the peroxidase activity. Adaptation of bacteria to amphiphilic antimicrobial compounds, which is accompanied by chemical changes in their lipid A, only slightly reduced their immunomodulatory activity when compared with the analogue from the sensitive strain. On the other hand, the diphosphoryl analogues were less active than MLA.
See more in PubMed
J Chromatogr A. 1997 Apr 11;767(1-2):53-61 PubMed
Folia Microbiol (Praha). 1988;33(6):433-9 PubMed
Infect Immun. 1999 Dec;67(12):6286-92 PubMed
J Leukoc Biol. 2001 Sep;70(3):381-5 PubMed
J Biol Response Mod. 1986 Oct;5(5):462-9 PubMed
Eur J Biochem. 1979 Nov;101(2):571-9 PubMed
Folia Microbiol (Praha). 1994;39(3):197-202 PubMed
J Immunol. 2002 Jan 15;168(2):926-32 PubMed
J Mol Cell Cardiol. 1998 Jan;30(1):3-17 PubMed
Arzneimittelforschung. 1996 Jan;46(1):64-7 PubMed
Infect Immun. 1999 May;67(5):2515-21 PubMed
Biochim Biophys Acta. 2000 Jun 1;1466(1-2):87-104 PubMed
Microbios. 2001;106(414):97-110 PubMed
Scand J Clin Lab Invest Suppl. 1968;97:31-50 PubMed
Pharmazie. 1990 Sep;45(9):695-6 PubMed
Folia Microbiol (Praha). 1995;40(3):283-7 PubMed
Antiviral Res. 1990 Jun;13(6):327-33 PubMed
Naturwissenschaften. 1978 Nov;65(11):578-85 PubMed
Infect Immun. 1998 Aug;66(8):3569-78 PubMed
